Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | APEX1 | P27695 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13568574 | 0.84 | NR1H4 (0.58) | POLBL3MBTL1CTDSP1TDP1APEX1 | |
| SCHEMBL12222500 | 0.80 | POLB (0.67) | NOTUMPOLBL3MBTL1CTDSP1TDP1 | |
| SCHEMBL13471704 | 0.80 | NOTUM (0.65) | NOTUMPOLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL13754330 | 0.78 | NOTUM (0.63) | NOTUMPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL645648 | 0.78 | POLB (0.68) | NOTUMPOLBL3MBTL1CTDSP1TDP1 | |
| SCHEMBL14154502 | 0.77 | NOTUM (0.60) | NOTUMPOLBALDH1A1LMNAMAPT | |
| SCHEMBL6315486 | 0.76 | NOTUM (0.59) | NOTUMPOLBL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL3102569 | 0.74 | CYP1A2 (0.43) | NOTUMPOLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL15331958 | 0.74 | POLB (1.00) | POLBL3MBTL1CTDSP1TDP1APEX1 | |
| SCHEMBL11622218 | 0.73 | NOTUM (0.56) | NOTUMPOLBTDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| EP-3226858-B1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2021-02-03 | — | — | EP | disclosed |
| US-10456379-B2 | Imidazole-based antimicrobial agents | PROCOMCURE BIOTECH GMBH (AT) | 2019-10-29 | — | — | US | disclosed |
| EP-1893210-B1 | SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 | UNIV ILLINOIS (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019152731-A1 | ANDROGEN RECEPTOR ANTAGONISTS | ALPINE ANDROSCIENCES, INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10322110-B2 | Imidazole-based antimicrobial agents | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-18 | — | — | US | disclosed |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-11 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3148997-B1 | HELQUATS WITH HETEROAROMATIC SUBSTITUENTS, PREPARATION THEREOF, AND USE THEREOF AS G-QUADRUPLEX STABILIZERS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2018-06-27 | — | — | EP | disclosed |
| WO-2006074025-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1653954-A1 | ANTIBIOTIC THIAZOLIDINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-05-10 | — | — | EP | disclosed |
| CN-1671386-A | Substituted anilinic piperidines as MCH selective antagonists | LUNDBECK & CO AS H (DK) | 2005-09-21 | — | — | CN | disclosed |
| CN-1607202-A | Novel antibiotic compounds, pharmaceutical compositions containing them and their use | JEAN-PAUL LEONETTI (FR) | 2005-04-20 | — | — | CN | disclosed |
| WO-2005020990-A1 | ANTIBIOTIC THIAZOLIDINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-03-10 | — | — | WO | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456379-B2 | Imidazole-based antimicrobial agents | TLR5, NISCH, SLC11A2 | NOTUM 2202/4885POLB 1637/4885L3MBTL1 2175/4885 |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | NOTUM 1441/4885POLB 1547/4885L3MBTL1 869/4885 |
| US-10322110-B2 | Imidazole-based antimicrobial agents | ARG1, SLC11A2, IKZF3 | NOTUM 3558/4885POLB 3215/4885L3MBTL1 1528/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | NOTUM 1311/4885POLB 1306/4885L3MBTL1 1616/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | NOTUM 1311/4885POLB 1306/4885L3MBTL1 1616/4885 |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | MIF, SLC11A2, TLR5 | NOTUM 1984/4885POLB 1569/4885L3MBTL1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.